Lisata Therapeutics (LSTA) Expected to Release Earnings on Thursday

Lisata Therapeutics (NASDAQ:LSTA) will likely be issuing its results before the market opens on Thursday, November 5th. Analysts expect Lisata Therapeutics to post earnings of ($1.1250) per share and revenue of $0.66 million for the quarter.

Lisata Therapeutics (NASDAQ:LSTA) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.32) earnings per share (EPS) for the quarter.

Lisata Therapeutics Stock Performance

NASDAQ LSTA opened at $1.01 on Tuesday. The stock has a market cap of $10.91 million, a price-to-earnings ratio of -0.62 and a beta of 1.04. The business has a 50 day simple moving average of $1.38 and a 200 day simple moving average of $2.97. Lisata Therapeutics has a 52-week low of $0.96 and a 52-week high of $5.07.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce”.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company’s approach is designed to improve the delivery and effectiveness of cancer treatments by targeting the tumor microenvironment, which can limit the penetration of medicines into tumors.

Lisata’s lead investigational product is certepetide, formerly known as CEND-1. Certepetide is a tumor-penetrating peptide intended to selectively home to tumor tissue and temporarily modify the tumor microenvironment, potentially helping co-administered anticancer therapies reach cancer cells more effectively.